Centers for Medicare & Medicaid Services approves Elsevier’s ClinicalPath as an evidence-based guideline for use under the new Enhanced Oncology Model

Elsevier, a global leader in evidence-based clinical practice content, research publishing and information analytics, today announced that their evidence-based oncology pathways solution, ClinicalPath, has been approved by the Centers for Medicare & Medicaid Services (CMS) as a clinical guideline for oncology practices participating in the new Enhanced Oncology Model (EOM).  With this designation as an approved evidence-based guideline, oncology practices participating in EOM will be able to use ClinicalPath in accordance with the EOM participant redesign, one of the first products of its type to receive such approval.

EOM is a five-year voluntary model for oncology practices, an initiative launched by CMS, a federal agency of the Department for Health and Human Services (HHS). EOM will come into effect on July 1 2023, with practices opting to participate in EOM being incentivized to consider the whole patient journey and proactively engage with patients.

EOM is CMS’s newest value-based care model, building on the previous Oncology Care Model (OCM), a six-year program that ran from 2016-2022. EOM takes further steps to encourage cancer care to focus more on the patient.

Oncology practices participating in EOM are required to implement participant redesign activities including care planning, use of evidence-based guidelines, use of data for continuous quality improvement, and more. ClinicalPath presents evidence-based oncology pathways embedded in the clinical workflow to help care teams make consistent, well-informed decisions for high quality care. The associated analytics within ClinicalPath enable accurate tracking of patterns of care and outcomes.

Dr. Paul J. Helmuth, MD, Physician Clinical Executive at Elsevier said: “We are delighted to have received this approval from CMS and hugely proud to be one of the first products in the market to have this status. ClinicalPath utilizes advanced technology and data insights to help healthcare professionals make consistent decisions, making it closely aligned with the aspirations for personalized, joined up cancer care as outlined in EOM.  At Elsevier, we are committed to enhancing patient outcomes, and we are delighted that through ClinicalPath, we will be able to support all EOM-participating oncology practices in providing better care to oncology patients.”

---

Notes to editors

About ClinicalPath

ClinicalPath (formerly Via Oncology) provides industry-leading oncology pathways used by health systems, academic medical centers, and private practices across the US and globally. Designed to help reduce variability in care and support optimal patient outcomes, ClinicalPath is delivered at the point of care, using a workflow-embedded decision support tool and advanced EHR integration.

About Elsevier

Elsevier is a global leader in advanced information and decision support. For over a century, we have been helping advance science and healthcare to advance human progress. We support academic and corporate research communities, doctors, nurses, future healthcare professionals and educators across 170 countries in their vital work. We do this by delivering mission-critical insights and innovative solutions that combine trusted, evidence-based scientific and medical content with cutting-edge AI technologies to help impact makers achieve better outcomes. We champion inclusion and sustainability by embedding these values into our products and culture, working with the communities that we serve. The Elsevier Foundation supports research and health partnerships around the world.

Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. For more information, visit www.elsevier.com and follow us on social media @ElsevierConnect.